White Paper

Process Monitoring And Data Management Approaches For Today's Bioprocess Challenges

By Carnley Norman, Vice President of Manufacturing Operations at KBI Biopharma, and Anshuman Bansal, Head of Process Analytics, BioContinuum™ Platform at Merck KGaA, Darmstadt, Germany

biopharma manufacturing manfuracturer

The inherent molecular complexity and vulnerability of biologic drugs to their surrounding conditions makes the manufacturing process for them challenging and complex. As opposed to small molecule drugs, which are synthesized through chemicals, large molecule biologic drugs (produced using living cellular organisms) have significant variability in how they function and perform. Therefore, any factors that can affect their robustness and quality during manufacturing must be understood in order to design a manufacturing process that consistently delivers a safe and effective drug. Sources of variation include a drug manufacturing’s cellular environmental conditions, the raw materials used, the behavior of the biologic itself, and even the equipment used for manufacturing. If these sources of variations are not well understood and are not tamed at their roots, they usually result in a butterfly effect. Propagation of these variations through the processing stages can lead to catastrophic and uncontrolled outcomes and process failures.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: